Linking differential radiation responses to glioma heterogeneity

Oncotarget

Volumn 5, Issue 6, 2014, Pages 1657-1665

  Ke, Chao ^a,b   Tran, Katherine ^a   Chen, Yumay ^a   di Donato, Anne T ^a   Yu, Liping ^a   Hu, Yuanjie ^a   Linskey, Mark E ^a   Wang, Ping H ^a   Limoli, Charles L ^a   Zhou, Yi Hong ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Cellular heterogeneity; Glioma; Metabolic state; Radiosensitivity; Redox homeostasis; Tumorigenicity

Indexed keywords

ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL HETEROGENEITY; CELL SUBPOPULATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC VARIABILITY; GLIOMA; GLIOMA CELL LINE; GLYCOLYSIS; HUMAN; HUMAN CELL; IONIZING RADIATION; KARYOTYPE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PHENOTYPE; RADIATION RESPONSE; RADIOSENSITIVITY; SKULL IRRADIATION; TUMOR GROWTH; TUMOR SPHEROID; APOPTOSIS; CELL PROLIFERATION; CFU COUNTING; CLASSIFICATION; ENERGY METABOLISM; FLOW CYTOMETRY; MULTICELLULAR SPHEROID; PATHOLOGY; RADIATION DOSE; TUMOR CELL CULTURE;

APOPTOSIS; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; ENERGY METABOLISM; FLOW CYTOMETRY; GLIOMA; GLYCOLYSIS; HUMANS; OXIDATIVE PHOSPHORYLATION; RADIATION TOLERANCE; RADIATION, IONIZING; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 84904264833     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1823     Document Type: Article

References (32)

1. Marusyk A and Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010; 1805(1):105-117.
2. Fidler IJ and Hart IR. Biological diversity in metastatic neoplasms: origins and implications. Science. 1982; 217(4564):998-1003.
3. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, Paulson TG, Blount PL, Risques RA, Rabinovitch PS and Reid BJ. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet. 2006; 38(4):468-473.
4. Merlo LM, Pepper JW, Reid BJ and Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer. 2006; 6(12):924-935.
5. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C and Lander ES. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011; 146(4):633-644.
6. Hu Y, Ru N, Xiao H, Chaturbedi A, Hoa NT, Tian XJ, Zhang H, Ke C, Yan F, Nelson J, Li Z, Gramer R, Yu L, Siegel E, Zhang X, Jia Z, et al. Tumor-specific chromosome mis-segregation controls cancer plasticity by maintaining tumor heterogeneity. PLoS One. 2013; 8(11):e80898.
7. Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, Reed R, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014; 343(6166):72-76.
8. Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F, D'Alessio AC, Young RA and Weinberg RA. Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity. Cell. 2013; 154(1):61-74.
9. Munoz DM and Guha A. Mouse models to interrogate the implications of the differentiation status in the ontogeny of gliomas. Oncotarget. 2011; 2(8):590-598.
10. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110.
11. Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, Ozawa T, Holland EC, Huse JT, Jhanwar S, Leversha MA, Mikkelsen T and Brennan CW. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A. 2012; 109(8):3041-3046.
12. Limoli CL, Giedzinski E, Baure J, Rola R and Fike JR. Altered growth and radiosensitivity in neural precursor cells subjected to oxidative stress. Int J Radiat Biol. 2006; 82(9):640-647.
13. Limoli CL, Giedzinski E, Rola R, Otsuka S, Palmer TD and Fike JR. Radiation response of neural precursor cells: linking cellular sensitivity to cell cycle checkpoints, apoptosis and oxidative stress. Radiat Res. 2004; 161(1):17-27.
14. Acharya MM, Lan ML, Kan VH, Patel NH, Giedzinski E, Tseng BP and Limoli CL. Consequences of ionizing radiation-induced damage in human neural stem cells. Free Radic Biol Med. 2010; 49(12):1846-1855.
15. Lan ML, Acharya MM, Tran KK, Bahari-Kashani J, Patel NH, Strnadel J, Giedzinski E and Limoli CL. Characterizing the radioresponse of pluripotent and multipotent human stem cells. PLoS One. 2012; 7(12):e50048.
16. Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M, Popescu R, Della Donna L, Evers P, Dekmezian C, Reue K, Christofk H, Mischel PS and Pajonk F. Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci U S A. 2011; 108(38):16062-16067.
17. Nakano I, Masterman-Smith M, Saigusa K, Paucar AA, Horvath S, Shoemaker L, Watanabe M, Negro A, Bajpai R, Howes A, Lelievre V, Waschek JA, Lazareff JA, Freije WA, Liau LM, Gilbertson RJ, et al. Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. J Neurosci Res. 2008; 86(1):48-60.
18. Joshi K, Banasavadi-Siddegowda Y, Mo X, Kim SH, Mao P, Kig C, Nardini D, Sobol RW, Chow LM, Kornblum HI, Waclaw R, Beullens M and Nakano I. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells. 2013; 31(6):1051-1063.
19. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas F, Somlo G, Garberoglio C, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009.
20. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-760.
21. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB. Identification of human brain tumour initiating cells. Nature. 2004; 432(7015):396-401.
22. Colin C, Baeza N, Tong S, Bouvier C, Quilichini B, Durbec P and Figarella-Branger D. In vitro identification and functional characterization of glial precursor cells in human gliomas. Neuropathol Appl Neurobiol. 2006; 32(2):189-202.
23. Kahlert UD, Bender NO, Maciaczyk D, Bogiel T, Bar EE, Eberhart CG, Nikkhah G and Maciaczyk J. CD133/CD15 defines distinct cell subpopulations with differential in vitro clonogenic activity and stem cell-related gene expression profile in in vitro propagated glioblastoma multiformederived cell line with a PNET-like component. Folia Neuropathol. 2012; 50(4):357-368.
24. Prestegarden L, Svendsen A, Wang J, Sleire L, Skaftnesmo KO, Bjerkvig R, Yan T, Askland L, Persson A, Sakariassen PO and Enger PO. Glioma cell populations grouped by different cell type markers drive brain tumor growth. Cancer Res. 2010; 70(11):4274-4279.
25. Mazzoleni S, Politi LS, Pala M, Cominelli M, Franzin A, Sergi Sergi L, Falini A, De Palma M, Bulfone A, Poliani PL and Galli R. Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumorinitiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res. 2010; 70(19):7500-7513.
26. Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, Foran I, Yong WH, Vinters HV, Liau LM, Lazareff JA, Mischel PS, Cloughesy TF, Horvath S and Kornblum HI. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells. 2009; 27(4):980-987.
27. Patru C, Romao L, Varlet P, Coulombel L, Raponi E, Cadusseau J, Renault-Mihara F, Thirant C, Leonard N, Berhneim A, Mihalescu-Maingot M, Haiech J, Bieche I, Moura-Neto V, Daumas-Duport C, Junier MP, et al. CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer. 2010; 10:66.
28. Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI, Jeon JW, Kim MH, Kang BG, Jung Y, Jin J, Hong SC, Park WY, Lee DS, Kim H and Nam DH. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest. 2008; 88(8):808-815.
29. Sun Y, Kong W, Falk A, Hu J, Zhou L, Pollard S and Smith A. CD133 (Prominin) negative human neural stem cells are clonogenic and tripotent. PLoS One. 2009; 4(5):e5498.
30. Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SO, Svendsen A, Prestegarden L, Rosland G, Thorsen F, Stuhr L, Molven A, Bjerkvig R and Enger PO. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer. 2008; 122(4):761-768.
31. Griguer CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, Lancaster JR, Jr. and Gillespie GY. CD133 is a marker of bioenergetic stress in human glioma. PLoS One. 2008; 3(11):e3655.
32. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB and Rich JN. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009; 15(6):501-513.